At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 939 enrolled
Drug / intervention
Abicipar Pegol +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)
In Brief
A Phase 3 clinical trial evaluating Abicipar Pegol, Ranibizumab, and 1 other intervention for Macular Degeneration. Completed, enrolled 939 participants across 151 sites in 17 countries.
Detailed Summary
This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesArgentina, Austria, Chile, Colombia, Czechia, France, Germany, Hong Kong, Israel, Latvia, New Zealand, Philippines, Singapore, South Korea, Spain, Switzerland, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartJun 2015
Primary CompletionApr 2018
Study CompletionJun 2019
TodayJul 2026
First PostedJun 4, 2015
Enrollment StartJun 25, 2015
Primary CompletionApr 18, 2018
Study CompletionJun 19, 2019
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.1 years ago
Interventions
Abicipar Pegoldrug
Abicipar pegol intravitreal injection.
Ranibizumabdrug
Ranibizumab intravitreal injection.
Sham Procedureother
Sham injection.